Pharsight

Durysta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8629185 ALLERGAN INC 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Jul, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10398707 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related implants
Apr, 2024

(a month from now)

US8673341 ALLERGAN INC Intraocular pressure reduction with intracameral bimatoprost implants
Feb, 2025

(10 months from now)

US9149428 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use
Dec, 2026

(2 years from now)

US10441543 ALLERGAN INC Processes for making cyclic lipid implants for intraocular use
Dec, 2026

(2 years from now)

US8206737 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2027

(3 years from now)

US7799336 ALLERGAN INC Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2029

(5 years from now)

US9980974 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(10 years from now)

US9492316 ALLERGAN INC Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(10 years from now)

Durysta is owned by Allergan Inc.

Durysta contains Bimatoprost.

Durysta has a total of 9 drug patents out of which 0 drug patents have expired.

Durysta was authorised for market use on 04 March, 2020.

Durysta is available in implant;ophthalmic dosage forms.

Durysta can be used as reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant.

The generics of Durysta are possible to be released after 31 October, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Product (NP) Mar 4, 2023

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

DURYSTA family patents

Family Patents